Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with a 15% QoQ revenue increase and an 89% YoY growth, alongside strategic product developments and expansion plans. Despite some uncertainties in data maturity and profitability guidance, the company's solid cash position and reduced operating expenses highlight financial discipline. The Q&A session reflects management's cautious optimism, with positive updates on trial progress and market expansion. Given the market cap of approximately $1.2 billion, the stock is likely to react positively, with potential gains in the 2% to 8% range over the next two weeks.
Key Financial Performance
Net Product Revenue (Q3 2025) $38.5 million, representing a 15% quarter-over-quarter increase. This growth was driven by increased adoption, significant and durable treatment persistence, and growing confidence in OJEMDA's differentiated profile.
Total Prescriptions (Q3 2025) Over 1,200 total prescriptions, an 18% increase quarter-over-quarter. This was fueled by acceleration in new patient starts, enhanced physician confidence due to 2-year follow-up data, and increased adoption in the second-line.
New Patient Starts (Q3 2025) Accelerated by almost 20% quarter-over-quarter. This was driven by the release of 2-year follow-up data from FIREFLY-1, which enhanced physician confidence in OJEMDA's durable efficacy and reversibility of growth velocity delays.
Year-to-Date Net Product Revenue (2025) $102.6 million, reflecting an 89% increase over full year 2024. This growth was driven by underlying patient demand and prescription trends.
Operating Expenses (Q3 2025) $59.6 million, including $9.6 million of noncash stock-based compensation. This represents a 9% decline compared to Q2 2025, reflecting a data-driven approach to capital allocation and prioritization of high-return investments.
Cash Position (End of Q3 2025) $451.6 million with no debt. This reflects a slight decrease from the prior quarter due to investments in advancing commercial and pipeline priorities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OJEMDA's performance: Accelerated growth in new patient starts, total prescriptions, and net product revenue. Delivered $38.5 million in net product revenue, a 15% quarter-over-quarter increase.
FIREFLY-1 data: 2-year data included in OJEMDA label shows manageable safety profile and durable clinical benefit. Median duration of response increased from 13 to 18 months.
Pipeline advancements: Ipsen anticipates mid-2026 EMA approval decision for OJEMDA. FIREFLY-2 Phase III trial on track for full enrollment in H1 2026. DAY301 advancing with dose escalation in Phase Ia trial.
Market expansion in Europe: Ipsen anticipates EMA approval decision for OJEMDA in mid-2026, marking a step toward European market entry.
Adoption in second-line treatment: Second-line adoption grew over 60% in the past 12 months. OJEMDA increasingly becoming the treatment of choice for second-line pLGG.
Revenue growth: Net product revenue rose 15% to $38.5 million in Q3. Year-to-date revenue reached $102.6 million, an 89% increase over full-year 2024.
Expense management: Operating expenses declined 9% compared to Q2, reflecting disciplined capital allocation. Revenue exceeded combined cost of sales and SG&A for the first time.
Revenue guidance increase: Raised full-year 2025 revenue guidance to $145 million to $150 million, reflecting confidence in OJEMDA's growth trajectory.
Business development: Actively evaluating opportunities to complement commercial capabilities and long-term strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is awaiting a mid-2026 EMA approval decision for OJEMDA in Europe, which represents a regulatory hurdle and potential delay in market expansion.
Clinical Trial Enrollment: The FIREFLY-2 global Phase III trial is on track for full enrollment in the first half of 2026, but any delays in enrollment could impact the timeline for OJEMDA's potential move into frontline pLGG in the U.S.
Expense Management: While the company has shown disciplined expense management, there is an expectation of increased expenses in Q4 due to planned commercial and clinical activities, which could impact profitability.
Market Adoption: Although OJEMDA has shown strong adoption in the second-line treatment of pLGG, there is still considerable opportunity for further adoption, indicating that market penetration is not yet fully realized.
Supply Chain Management: The company is actively managing channel stock levels to align with demand, but any misalignment could lead to supply constraints or overstocking.
Economic and Financial Risks: The company is not yet guiding to profitability, and while cash burn has improved, financial discipline remains critical to sustain operations and long-term value creation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its full-year revenue guidance for 2025 to a range of $145 million to $150 million, reflecting confidence in the trajectory of OJEMDA's launch and its durable growth.
European Market Expansion: Ipsen, the company's partner, anticipates a mid-2026 EMA approval decision for OJEMDA, which would enable its entry into the European market.
FIREFLY-2 Trial: The global Phase III FIREFLY-2 trial is on track for full enrollment in the first half of 2026, potentially positioning OJEMDA for frontline pLGG treatment in the U.S.
DAY301 Development: The PTK7-directed ADC, DAY301, is advancing with dose escalation ongoing in the Phase Ia trial.
Clinical Data Updates: Three-year FIREFLY-1 data will be presented later this month, with a full manuscript expected in the first half of next year. These data will provide a longer-term view of OJEMDA's safety and efficacy.
Operational Priorities: The company aims to drive OJEMDA adoption as the standard of care in second-line pLGG, advance its pipeline, and maintain disciplined expense management to achieve profitability.
Commercial Growth: The company expects continued double-digit sequential growth in Q4 2025, supported by strong physician confidence and compelling clinical data.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What impact are you seeing on the rate of discontinuations and duration of therapy, especially in non-EAP patients?
A:The data is still maturing for commercial patients, but the median duration of therapy in EAP patients is 20 months. This number may evolve as more patients reach 24 months of therapy. For non-EAP commercial patients, it is too early to provide specific data.
Q:What are you looking for in the 3-year data for the pivotal FIREFLY-1 study?
A:The focus is on time-to-event analysis, including time to next treatment, treatment-free interval, and progression. Additionally, the study will examine rebound tumor growth after stopping therapy and the stability of tumors post-treatment.
Q:How has the addition of FIREFLY data to the label impacted off-label MEK inhibitor usage?
A:It is too early to determine the impact, but the NCCN listing for OJEMDA in adult gliomas could influence off-label use. However, the commercial team cannot engage with physicians on this topic due to label restrictions.
Q:Did you see any gross-to-net changes in Q3?
A:The gross-to-net rate was at the high end of the 12%-15% range due to a CPIU penalty from a price increase on July 1. Relief on the CPIU is expected in Q4.
Q:How is enrollment for DAY301 progressing, and what are your thoughts on PTK7 as a target?
A:Enrollment is proceeding as expected, with no issues. PTK7 is considered a sound target for oncology development, and distinctions in payloads between therapeutics are noted.
Q:Can you provide commentary on the patient population breakdown by line of therapy?
A:Data is limited and based on self-reported physician behavior. There has been a 60% growth in second-line usage over the past 12 months.
Q:How impactful is long-term data versus firsthand experience in gaining physician uptake?
A:Both are important, but recent ASCO data on growth velocity has been particularly impactful in increasing physician confidence in prescribing OJEMDA.
Q:What should we focus on in the 3-year update for FIREFLY-1?
A:Focus on whether there is tumor rebound growth after stopping therapy and the stability of tumors for a year post-treatment. A key metric is the percentage of patients not requiring therapy one year after stopping treatment.
Q:What is the concentration of patients in physician offices, and is there room for growth?
A:There is significant room for growth, especially in Priority 1 accounts, which have a considerable volume of patients.
Q:Are all new patient starts (NPS) equal, and are there differences in persistence or dose modification needs?
A:Second-line patients are more desirable due to a larger pool and less complicated health profiles. Dose modification is important for AE management and does not impact pricing.
Q:Review of Unclear Management Responses
A:Management avoided providing specific data on the impact of discontinuations and duration of therapy for non-EAP commercial patients, stating it was too early to say. They also did not provide a clear answer on the potential impact of the NCCN listing on off-label MEK inhibitor usage, citing label restrictions and the early stage of observation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Annual Meeting
EAP patient
Financial Results
Neuro Oncology
OJEMDA patient
OJEMDA profile
OJEMDA treatment
Oncology Annual
Priority account
Society Neuro
acceleration
adoption OJEMDA
adoption line
analysis
brand
choice line
digit
driver
excellence
graph
indicator
layer
momentum
month FIREFLY
patient insight
persistence moment
persistency
physician OJEMDA
prescribing account
prescription patient
presentation Society
product increase
term view
treatment choice
treatment month
treatment patient
velocity
DAWN Transcript
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary indicates strong financial performance with 25% revenue growth and 50% net income increase, alongside optimistic strategic initiatives and revenue expectations. The raised revenue guidance for 2025 and ongoing product development efforts further support a positive outlook. However, the lack of shareholder return plans and potential risks mentioned slightly temper this optimism. Given the company's mid-cap status, a positive stock price movement (2% to 8%) is anticipated over the next two weeks.
Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong financial performance with a 15% QoQ revenue increase and an 89% YoY growth, alongside strategic product developments and expansion plans. Despite some uncertainties in data maturity and profitability guidance, the company's solid cash position and reduced operating expenses highlight financial discipline. The Q&A session reflects management's cautious optimism, with positive updates on trial progress and market expansion. Given the market cap of approximately $1.2 billion, the stock is likely to react positively, with potential gains in the 2% to 8% range over the next two weeks.
Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong financial performance with a 10% increase in net product revenue and disciplined cost control. The Q&A section reveals positive sentiment towards new patient starts and physician confidence, supported by promising ASCO data. Despite some uncertainties in portfolio diversification and economic conditions, the company's strong cash position and strategic focus on OJEMDA provide a positive outlook. Given the market cap of $1.2 billion, the stock price is likely to see a positive movement of 2% to 8% over the next two weeks.
DAWN Slides
DAWN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
